Proliferative markers, such as Ki‐67, PCNA, PHH3, and Cyclin D1, have been investigated for their potential use as predictive and prognostic biomarkers in pancreatic cancer chemotherapy. This evidence concerns the gene CCND1 and familial pancreatic carcinoma.